Shopping Cart
- Remove All
- Your shopping cart is currently empty
PI4KIII beta inhibitor 3 is a novel, highly effective inhibitor of PI4KIIIβ with an IC50 of 5.7 nM.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
500 μg | $253 | 35 days | |
1 mg | $480 | 35 days |
Description | PI4KIII beta inhibitor 3 is a novel, highly effective inhibitor of PI4KIIIβ with an IC50 of 5.7 nM. |
Targets&IC50 | PI4KIIIβ:5.7 nM |
In vitro | PI4KIII beta inhibitor 3 is a potent PI4KIII inhibitor with an IC50 of 5.7 nM. It exhibits significant immunosuppressive activity in the mixed lymphocyte reaction (MLR) assay with an IC50 of 3 nM and inhibits IL2 and IFNγ secretion with IC50 values of less than 1 nM, demonstrating effectiveness comparable to cyclosporine A, whose IC50 values for IFNγ and IL2 release are 2 nM and less than 1 nM, respectively [1]. |
In vivo | Oral administration of PI4KIII beta inhibitor 3 results in prolonged graft survival in 3 out of 6 grafts in each group at day 30. Several grafts continued beating after withdrawal of the treatment (up to 60 days), indicating the induction of a certain type of graft tolerance. To evaluate the operational tolerance phenotype, animals with functional graft at day 60 are challenged with a second graft from the same donor strain or from a third party. |
Molecular Weight | 446.53 |
Formula | C22H22N8OS |
Cas No. | 1245319-54-3 |
Relative Density. | 1.432 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
Solubility Information | DMSO: 20 mg/mL (44.79 mM), Sonication is recommended. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.